10 completed, 3 terminated, 2 withdrawn, 1 active not recruiting. 17 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 10, Terminated 3, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 3 | Completed 3 |
Follow Alopecia universalis: new trials by email Literature Review of Alopecia universalis trials Research Report on Alopecia universalis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata Vancomycin, Neomycin and MTT capsules, Placebo capsules - Alopecia Areata, Alopecia Totalis | Phase 2 | Recruiting | University of Minnesota | 40 | 2025-08-21 | 2026-06-26 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata EQ101 - Alopecia Areata, Alopecia | Phase 2 | Completed | Equillium | 36 | 2022-12-19 | 2025-04-10 |
| Clinical Application of Stem Cell Educator Therapy in Alopecia Areata Stem Cell Educator therapy - Alopecia Areata, Alopecia Totalis | Phase 2 | Active not recruiting | Throne Biotechnologies Inc. | 20 | 2022-09-20 | 2026-09-30 |
| Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata BNZ-1, Normal saline - Alopecia Areata, Alopecia Totalis | Phase 2 | Withdrawn | Equillium | 2021-10-01 | 2022-09-16 | |
| PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA PF-06651600, Placebo - Alopecia Areata | Phase 2 | Terminated | Pfizer | 71 | 2020-09-15 | 2025-07-11 |
| Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata Fecal material transfer therapy, 4mm Punch Biopsy of Scalp, Blood draw - Alopecia Areata, Alopecia Totalis | Phase 2 | Withdrawn | Lindsey Bordone | 2019-12-19 | 2022-03-21 | |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) ATI 502 0.46% Topical Solution - Alopecia Areata, Alopecia Universalis | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 56 | 2019-01-15 | 2020-10-06 |
| PF-06651600 for the Treatment of Alopecia Areata PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2 - Alopecia Areata | Phase 2 / Phase 3 | Completed | Pfizer | 718 | 2018-12-03 | 2022-02-24 |
| Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata ATI-50002 - Alopecia Areata, Alopecia Totalis | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 1 | 2018-04-11 | 2019-12-11 |
| Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Dupilumab, Placebo - Alopecia Areata | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 60 | 2018-01-09 | 2022-09-13 |
| Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) Vehicle, ATI-50002 - Alopecia Universalis (AU), Alopecia Totalis (AT) | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 11 | 2017-12-14 | 2020-07-02 |
| Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Tofacitinib ointment - Alopecia Areata, Alopecia Totalis | Phase 2 | Completed | Yale University | 10 | 2016-09-01 | 2019-01-30 |
| A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Tralokinumab, Placebo - Alopecia Areata | Phase 2 | Completed | Emma Guttman | 22 | 2016-01-01 | 2020-01-07 |
| A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) Placebo Cream, Ruxolitinib Phosphate Cream - Alopecia Areata | Phase 2 | Terminated | Incyte Corporation | 90 | 2015-11-18 | 2020-12-16 |
| Tofacitnib for the Treatment of Alopecia Areata and Variants Tofacitinib Administration - Alopecia Areata (AA), Alopecia Totalis (AT) | Phase 2 | Completed | Yale University | 30 | 2014-07-01 | 2017-04-04 |
| The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Botulinum toxin A, Normal saline injection - Recalcitrant Alopecia Totalis, Recalcitrant Alopecia Universalis | Phase 2 / Phase 3 | Completed | Siriraj Hospital | 20 | 2009-12-01 | 2012-08-02 |
| Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Targretin Gel 1% - Alopecia Areata | Phase 2 / Phase 3 | Completed | M.D. Anderson Cancer Center | 46 | 2003-05-01 | 2012-08-02 |
Alopecia Areata (15) · Alopecia (8) · Hair Diseases (1)
Hypotrichosis (15) · Skin Diseases (15) · Skin and Connective Tissue Diseases (15) · Hair Diseases (14) · Pathological Conditions, Anatomical (8) · Pathological Conditions, Signs and Symptoms (8) · Alopecia (7)
Saline Solution (2) · Bexarotene (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Neomycin (1) · PF-06651600 (1) · Solutions (1) · Vancomycin (1) · dupilumab (1) · monooxyethylene trimethylolpropane tristearate (1) · ruxolitinib (1) · tralokinumab (1)
Aclaris Therapeutics, Inc. (3) · Equillium (2) · Pfizer (2) · Yale University (2) · Emma Guttman (1) · Icahn School of Medicine at Mount Sinai (1) · Incyte Corporation (1) · Lindsey Bordone (1) · M.D. Anderson Cancer Center (1) · Siriraj Hospital (1) · Throne Biotechnologies Inc. (1) · University of Minnesota (1)
United States (13) · Australia (3) · Canada (2) · Poland (2) · Argentina (1) · Chile (1) · China (1) · Colombia (1) · Czechia (1) · Germany (1) · Hungary (1) · Japan (1) · Mexico (1) · New Zealand (1) · Russia (1)
Brett King, MD (1) · Brett King, MD, PhD (1) · Emma Guttman, MD, PhD (1) · Emma Guttman, MD,PhD (1) · Kathleen Butler, MD (1) · Lindsey Bordone, MD (1) · Madeleine Duvic, MD (1) · Maria K Hordinsky, MD (1) · Rasthawathana Desomchoke, MD (1) · Rattapon Thoungtong, MD (1) · Supenya Varothai, MD (1) · Suthasinee Pattaravadee, B.Sc (1)
PMID 28619556, PMID 38263353, PMID 41917311, PMID 42481842, PMID 22233865, PMID 22833322, PMID 25896390, PMID 27699252, PMID 34460948, PMID 37062298, PMID 37403610, PMID 37707764, PMID 37917289, PMID 39254890, PMID 39328096, PMID 39441519, PMID 39962358, PMID 40261547, PMID 41005700, PMID 42823604
2018 (1)